Precision BioSciences, Inc. Stock

$4.30

3.86% yesterday

Nasdaq, Jun 27, 10:00 pm CET

ISIN

US74019P1084

Symbol

DTIL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Precision BioSciences, Inc. Stock price

$4.30

-231.20 98.17% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

+0.16 3.86%

ISIN

US74019P1084

Symbol

DTIL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$47.7m

Enterprise Value

$-7.2m

Net debt

$-54.9m

Cash

$77.2m

Shares outstanding

10.6m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

0.93 | 2.13

EV/Sales

negative | negative

EV/FCF

0.12

P/B

0.92

Financial Health

Equity Ratio

41.35%

Return on Equity

12.71%

ROCE

-39.36%

ROIC

Debt/Equity

0.45

Financials (TTM | estimate)

Revenue

$51.1m | $22.4m

EBITDA

$-41.9m | $-41.7m

EBIT

$-44.1m

Net Income

$-22.0m | $-65.4m

Free Cash Flow

$-59.0m

Growth (TTM | estimate)

Revenue

-11.11% | -67.39%

EBITDA

-36.46% | -77.98%

EBIT

-27.53%

Net Income

20.53% | -1,011.58%

Free Cash Flow

19.45%

Margin (TTM | estimate)

Gross

EBITDA

-81.97% | -186.19%

EBIT

-86.21%

Net

-42.99% | -291.69%

Free Cash Flow

-115.40%

EPS

$-2.36

FCF per Share

$-5.59

Short interest

5.08%

Employees

108.00

Rev per Employee

$640.00k

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Precision BioSciences, Inc. Stock Analysis

Unlock Scores for Free

??

10 Analysts have issued a Precision BioSciences, Inc. forecast:

9x Buy

90%

More details on Analyst Estimates Including Price Targets

10 Analysts have issued a Precision BioSciences, Inc. forecast:

Buy

90%

Hold

10%

Analyst Estimates with Stock Price Targets

Financial data from Precision BioSciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	51 51	11% 11% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	35 35	3% 3% 69%
- Research and Development Expense	58 58	11% 11% 113%
EBITDA	-42 -42	36% 36% -82%
- Depreciation and Amortization	2.17 2.17	44% 44% 4%
EBIT (Operating Income) EBIT	-44 -44	28% 28% -86%
Net Profit	-22 -22	21% 21% -43%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Precision BioSciences, Inc. Stock News

Neutral

Business Wire

●

3 days ago

Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation for PBGENE-DMD for the treatment of Duchenne mu...

Neutral

Business Wire

●

about one month ago

Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. “We started 2025 with strong momentum and a focus...

Neutral

Business Wire

●

about one month ago

Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced the strategic prioritization and acceleration of PBGENE-DMD, the Company's first-in-class in vivo gene editing approach for Duchenne Muscular D...

More Precision BioSciences, Inc. News

Company Profile

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.

Head office	United States
CEO	Michael Amoroso
Employees	108
Founded	2006
Website	precisionbiosciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now